Exploring the real-world use of trastuzumab emtansine in Ontario, Canada
Summary
Client: Hoffmann-La Roche Limited
Project ID: P2023-208/ 2025 0970 394 000
Research Question/Objectives: Kadcyla (trastuzumab emtansine) is a type of antibody-drug conjugate targeted therapy with two approved indications:
- Metastatic Breast Cancer (mBC)
- Kadcyla (trastuzumab emtansine for injection) monotherapy is indicated for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.
- Early Breast Cancer (eBC)
- Kadcyla monotherapy is indicated for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.
Objectives:
Primary Objective:
- To characterize the frequency and percentage of trastuzumab emtansine use, by indication overall and quarter and Local Health Integration Network (LHIN) with number of cycles
Status: Completed
Results: September 2025